Claims for Patent: 11,040,042

Summary for Patent: 11,040,042

Title:	Transient protection of normal cells during chemotherapy
Abstract:	This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Inventor(s):	Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Chapel Hill, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC)
Assignee:	G1 Therapeutics, Inc. (Research Triangle Park, NC)
Application Number:	16/886,309
Patent Claims:	1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the compound of the structure: ##STR00333## or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical composition is suitable for intravenous administration. 2. The pharmaceutical composition of claim 1, wherein the compound is in the form of a hydrochloride salt.